

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

MYLAN PHARMACEUTICALS INC.,  
Petitioner

v.

REGENERON PHARMACEUTICALS, INC.,  
Patent Owner

---

*Inter Partes* Review No.: IPR2021-00880

---

U.S. Patent No. 9,669,069 B2  
Filed: December 17, 2015  
Issued: June 6, 2017  
Inventor: George D. Yancopoulos

Title: USE OF A VEGF ANTAGONIST TO TREAT  
ANGIOGENIC EYE DISORDERS

---


**PETITIONER MYLAN PHARMACEUTICALS INC.'S  
POWER OF ATTORNEY PURSUANT TO 37 C.F.R. § 42.10(b)**

Pursuant to 37 C.F.R. § 42.10(b), Petitioner Mylan Pharmaceuticals Inc., hereby appoints the following practitioners as its attorneys to transact all business in the United States Patent & Trademark Office associated with its Petition for *Inter Partes* Review of U.S. Patent No. 9,669,069 B2:

Lead Counsel	Backup Counsel
<p>Paul J. Molino (Reg. No. 45,350) paul@rmmslegal.com</p> <p><u>Postal and Hand Delivery Address</u> Rakoczy Molino Mazzochi Siwik LLP 6 West Hubbard Street Chicago, IL 60654 Telephone: (312) 222-6300 Facsimile: (312) 843-6260</p> <p><b><i>Petitioner consents to email service at:</i></b> MYL_REG_IPR@rmmslegal.com</p>	<p>William A. Rakoczy (<i>pro hac vice</i> to be filed) wrakoczy@rmmslegal.com</p> <p>Heinz J. Salmen (<i>pro hac vice</i> to be filed) hsalmen@rmmslegal.com</p> <p>Neil B. McLaughlin (Reg. No. 70,810) nmclaughlin@rmmslegal.com</p> <p><u>Postal and Hand Delivery Address</u> Rakoczy Molino Mazzochi Siwik LLP 6 West Hubbard Street Chicago, IL 60654 Telephone: (312) 527-5127 Facsimile: (312) 843-6260</p>

The individual signing below has the authority to execute this document on behalf of Mylan Pharmaceuticals Inc.

Mylan Pharmaceuticals Inc.

By:  \_\_\_\_\_

Name: \_\_\_\_\_ Vinny Lee \_\_\_\_\_

Title: \_\_\_\_\_ Litigation Counsel \_\_\_\_\_

Date: \_\_\_\_\_ May 4, 2021 \_\_\_\_\_

**CERTIFICATE OF SERVICE**

The undersigned hereby certifies that a true and correct copy of the foregoing Petitioner Mylan Pharmaceuticals Inc.'s Power of Attorney Pursuant to 37 C.F.R. § 42.10(b) was served on May 5, 2021, via FedEx Priority Overnight on the Patent Owner at the correspondence address of record for U.S. Patent No. 9,669,069 B2 as evidenced in Public Pair:

Regeneron – Bozicevic Field & Francis LLP  
201 Redwood Shores Parkway  
Suite 200  
Redwood City, CA 94065

Regeneron Pharmaceuticals, Inc.  
770 Old Saw Mill River Road  
Tarrytown, NY 10591

/Paul J. Molino/  
Paul J. Molino (Reg. No. 45,350)